Evaluating TRAF3IP2 Levels and Atherosclerotic Plaque in Humans
The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human
This study is trying to see if the levels of a protein called TRAF3IP2 in the blood are linked to the buildup of plaque in the arteries of people getting heart tests.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Nanjing Medical University Academic / other |
| Locations | 1 site (Huai'an, Jiangsu) |
| Trial ID | NCT05945394 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the relationship between surem TRAF3IP2 levels and the development of atherosclerotic plaques in patients undergoing coronary angiography. Building on previous findings in mice, the study will enroll patients and measure their TRAF3IP2 levels using ELISA. The goal is to establish whether there is a significant association between these levels and the presence of atherosclerotic plaques in humans.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected coronary heart disease who are scheduled for coronary angiography.
Not a fit: Patients with advanced heart failure (NYHA III-IV), malignant tumors, acute infections, or thyroid dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of TRAF3IP2 in coronary heart disease, potentially leading to new diagnostic or therapeutic strategies.
How similar studies have performed: While previous studies have shown the role of TRAF3IP2 in animal models, this study is novel as it seeks to establish similar associations in humans.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with suspected coronary heart disease 2. patients received coronary angiography Exclusion Criteria: 1. NYHA III-IV 2. malignant tumor 3. acute infection 4. thyroid dysfunction
Where this trial is running
Huai'an, Jiangsu
- Huai'an First People's Hospital — Huai'an, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Geng Jin, MD
- Email: gj885258@163.com
- Phone: +86-17753124846
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.